Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.
Clin Infect Dis
; 50(4): 605-12, 2010 Feb 15.
Article
en En
| MEDLINE
| ID: mdl-20085491
ABSTRACT
BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (400 mg twice daily) plus optimized background therapy was generally well tolerated, with superior and durable antiretroviral and immunological efficacy, compared with optimized background therapy alone.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Pirrolidinonas
/
Infecciones por VIH
/
Fármacos Anti-VIH
Tipo de estudio:
Clinical_trials
Límite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Clin Infect Dis
Asunto de la revista:
DOENCAS TRANSMISSIVEIS
Año:
2010
Tipo del documento:
Article
País de afiliación:
Estados Unidos